Purespring Therapeutics’ Post

Join Dr. Joanna Barbara, #ADME Research Services and Products Site Head for BioIVT, to discover creative solutions to your #invitro #drugtransporters data problems. Researchers are confronted with practical challenges associated with compounds that are unstable, sticky or insoluble, resulting in convoluted or inconclusive results. In this webinar, Dr. Barbara will discuss practical methodologies to account for nonspecific binding and instability in transporter studies and creative solutions to explore perplexing initial results and generate useful data. Learn more or register now: https://hubs.ly/Q01ZDyPc0

Building a successful company in the biotech industry requires more than an innovative product that fills an unmet need in the market. It also requires dynamic leadership and an unyielding commitment to success. As the CEO of CytoAgents, Teresa Whalen, RPh leads a team of world-renowned clinical drug development experts and scientific advisory board members who are at the forefront of groundbreaking treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. Learn more about Teresa and the CytoAgents team here: https://lnkd.in/g7P29x3i #biotech #biotechleadership #biotechnology #cytokinereleasesyndrome #crs

Struggling with a particularly difficult drug when it comes to your transporter studies? Tune into this educational webinar by Dr. Joanna Barbara where she discusses practical methodologies to account for nonspecific binding and instability in transporter studies and creative solutions to exploring perplexing initial results & generate useful data.

Need a post-Thanksgiving break from turkey, football, and gearing up for holiday shopping? Join top minds from Merck, Genentech and the MD Anderson Cancer Center as they delve into advanced solutions in biotech. Learn about the latest innovations in research, from identifying complex analytes to enhancing LC runtimes. Tune into our on-demand webinar, 'Biopharma Innovations: Experts Leveraging Ion Mobility'. It's the perfect intellectual escape for your holiday weekend! https://hubs.ly/Q029DcGF0 #ondemand #thanksgiving #MassSpec #analyticalscientist #biopharma #webinar #ProteinCharacterization #HRIMAdvancements #TeamMassSpec #mobilion #bioanalytical #MassSpectrometry #SeparationSciences #SLIM #biopharma #biotherapeutics #Glycans #Isomerome #HRIM #molecules #peptides #oligos #antibodies #proteomics #metabolomics #Science #Research #MS #Bioinformatics #lipidomics #LCMS #HPLC MOBILion Systems, Inc. The Analytical Scientist

It’s frustrating for your research that a wealth of public experimental data exists, without standardization and meaning. Check out our webinar to learn how to overcome this by leveraging the synergy between QIAGEN Biomedical Knowledge Base #BKB and QIAGEN OmicSoft Lands to fuel your drug discovery programs. #drugdiscovery #bioinformatics ➡️ https://lnkd.in/efYAqghX

Tune in on Friday, December 1st at 12 pm EST to hear our Chief Medical Officer, Aaron Koenig MD and other experts speak to Xtalks about the challenges and opportunities in the rapidly evolving field of psychedelic drug development. Join the live webinar here: https://bit.ly/3sJbShm. #psychoplastogen #neuroplasticity #mentalhealth #biotech #healthemind #brainhealth #neuroplastogen

US-China tensions persist; Genmab’s $1.8B ADC bet; New obesity startup in town; ALS drug withdrawal; and more https://lnkd.in/gvApizXM Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

This FABulous team is doing FABulous work in the autoimmune space! I learn something new everytime I talk with them. Check out this article! I promise you'll learn something! (I had no idea genes from inactivated X-chromosomes are expressed. 😲 ) #drugdiscovery #womenshealth #autoimmunediseases #bispecifics #lifesciences

Targeted protein degradation #tpd is really picking up speed, and its role in drug research is huge. It's something we can't ignore. Projected to reach £3.6 billion by 2027, this sector is not merely thriving financially but also making big strides in scientific innovation. As the director of a life sciences recruitment company, I find this progression particularly significant. Beyond the concept of "molecular glue," the industry is actively seeking new ways to dispose of unwanted proteins, with implications for treatments in diseases, most prominently cancer.  The partnership between Astellas Pharma and Cullgen Inc. shows that companies big and small are ready to work together. This kind of teamwork could spark new ideas and combine different skills to solve complex problems. It's something that could really shake things up in the industry. Moreover, the application of protein degradation isn't just limited to cancer research. The potential for broader medical applications, including neurodegenerative diseases, adds another dimension to the ongoing work, extending its reach and impact. The growing interest in protein degradation presents career opportunities for professionals in the field and invites engagement with this evolving aspect of life sciences. I encourage those interested to explore the potential within this area. If you wish to discuss the opportunities or share insights related to targeted protein degradation, feel free to reach out to me at [email protected] https://lnkd.in/dg8VP9J8 #AspireLifeSciences #proteindegradation #protac #tpd